NEWSROOM

EAZE—SERVING 6 MILLION CUSTOMERS IN 100 CITIES IN SPITE OF COVID-19

Eaze’s innovative program is paving the way for a more equitable and inclusive future.

COVID-19, THE NEW NORMAL—AND A BETTER PATH

2020 YEAR OF THE SPAC

BIOTECH BOOMING DESPITE COVID-19 ECONOMY

AARP Magazine Features Eaze

Amivas Receives FDA Approval for Its Life-saving Treatment of Severe Malaria

MedTechFDA Authorizes Everlywell's Home Collection Kit For Use With Multiple COVID-19 Tests

FDA increases oversight, requirements for COVID-19 antibody tests

AstraZeneca vaults to the front of the Covid-19 vaccine race, teaming up to globalize Oxford candida

Pivotal Covid-19 study of remdesivir ‘met its primary endpoint,' is emergency authorization next?

MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market

Cannabis Sales Are Steady — for Now

A Look Into Eaze's $35M Equity Raise, Move Into Branded Cannabis Products

US dials up coronavirus response, BIO taps Vir's George Scangos to head committee coordinating Indus

Karyopharm spotlights PhIII results after controversial FDA approval

BD News and Analysis for Biotech and Pharma

Eaze To Announce $35 Million Equity Raise Completion, Launch Of Its Own Brands

The top 100 biopharma venture investors at the megabillions deal table

Warren Buffett’s Berkshire Hathaway settles on its first biotech investment